Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype

Breast Cancer Research

Volumn 10, Issue 6, 2008, Pages

  Zhou, Changhua ^a,b   Nitschke, Ashley M ^c   Xiong, Wei ^c   Zhang, Qiang ^a   Tang, Yan ^c   Bloch, Michael ^c   Elliott, Steven ^c   Zhu, Yun ^c   Bazzone, Lindsey ^c   Yu, David ^c,d   Weldon, Christopher B ^d   Schiff, Rachel ^e   McLachlan, John A ^c   Beckman, Barbara S ^c   Wiese, Thomas E ^a   Nephew, Kenneth P ^f   Shan, Bin ^c   Burow, Matthew E ^c   Wang, Guangdi ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b Chengdu Blood Center   (China)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Indiana University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAP2K5 PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; SMALL INTERFERING RNA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BREAST TUMOR; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; EPITHELIUM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LIQUID CHROMATOGRAPHY; MESODERM; METABOLISM; PATHOLOGY; PHENOTYPE; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL SURVIVAL; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITHELIUM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; MAP KINASE KINASE 5; MESODERM; MITOGEN-ACTIVATED PROTEIN KINASE 7; PHENOTYPE; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; TUMOR STEM CELL ASSAY;

EID: 63849257577     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2210     Document Type: Article

References (68)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627. 10.1146/annurev.med.53.082901.103929, 11818492.
3. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-15670. 28101, 9861027, 10.1073/pnas.95.26.15665.
4. Cowan KH, Batist G, Tulpule A, Sinha BK, Myers CE. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 1986, 83:9328-9332. 387131, 3540935, 10.1073/pnas.83.24.9328.
5. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986, 261:15544-15549.
6. Ogretmen B, McCauley MD, Safa AR. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance. Biochemistry 1998, 37:11679-11691. 10.1021/bi980573c, 9709006.
7. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993, 53:4443-4448.
8. Besada V, Diaz M, Becker M, Ramos Y, Castellanos-Serra L, Fichtner I. Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics 2006, 6:1038-1048. 10.1002/pmic.200500151, 16385476.
9. Liu Y, Liu H, Han B, Zhang JT. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 2006, 66:3248-3255. 10.1158/0008-5472.CAN-05-3801, 16540677.
10. Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 2007, 30:1545-1551.
11. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 1992, 52:5190-5197.
12. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7:131-142. 16493418, 10.1038/nrm1835.
13. Moody SE, Perez D, Pan T, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfranceseco KL, Cardiff RD, Chodosh LA. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209. 10.1016/j.ccr.2005.07.009, 16169465.
14. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. Int J Cancer 2006, 118:290-301. 10.1002/ijc.21355, 16080193.
15. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007, 31:277-283.
16. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006, 12:4147-4153. 10.1158/1078-0432.CCR-06-0038, 16857785.
17. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007, 14:3629-3637. 17909916, 10.1245/s10434-007-9583-5.
18. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008, 68:2391-2399. 10.1158/0008-5472.CAN-07-2460, 18381447.
19. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 11:8686-8698. 10.1158/1078-0432.CCR-05-1492, 16361555.
20. Peinado H, Olmeda D, Cano A. Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428. 10.1038/nrc2131, 17508028.
21. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer: observations in vitro and in vivo. Cells Tissues Organs 2007, 185:191-203. 10.1159/000101320, 17587825.
22. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 2005, 118:873-887. 10.1242/jcs.01634, 15713751.
23. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001, 11:372-377. 10.1016/S0962-8924(01)02064-5, 11514191.
24. Bates RC, Mercurio AM. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 2003, 14:1790-1800. 165077, 12802055, 10.1091/mbc.E02-09-0583.
25. Dong R, Wang Q, He XL, Chu YK, Lu JG, Ma QJ. Role of nuclear factor kappa B and reactive oxygen species in the tumor necrosis factor-alpha-induced epithelial-mesenchymal transition of MCF-7 cells. Braz J Med Biol Res 2007, 40:1071-1078. 10.1590/S0100-879X2007000800007, 17665043.
26. Schmelz K, Wieder T, Tamm I, Muller A, Essmann F, Geilen CC, Schulze-Osthoff K, Dorken B, Daniel PT. Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene 2004, 23:6743-6759. 10.1038/sj.onc.1207848, 15273737.
27. Xu J, Zhou JY, Wu GS. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res 2006, 66:10092-10099. 10.1158/0008-5472.CAN-06-1633, 17047073.
28. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS. Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 1998, 58:4940-4946.
29. Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 2004, 24:1473-1480.
30. Burow ME, Weldon CB, Chiang T-C, Tang Y, Collins-Burow BM, Rolfe K, Li S, McLachlan JA, Beckman BS. Differences in protein kinase C and estrogen receptor α/β expression and signaling correlate with apoptotic sensitivity of MCF-7 breast cancer cell variants. Int J Oncol 2000, 16:1179-1187.
31. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 2002, 132:293-301. 10.1067/msy.2002.125389, 12219026.
32. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng ASL, Li L, Abbosh PH, Huang TH-M, Nephew KP. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006, 66:11954-11966. 10.1158/0008-5472.CAN-06-1666, 17178894.
33. Zhou G, Bao ZQ, Dixon JE. Components of a new human protein kinase signal transduction pathway. J Biol Chem 1995, 270:12665-12669.
34. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912. 10.1126/science.1072682, 12471242.
35. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40. 10.1038/35065000, 11242034.
36. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17:548-558. 10.1016/j.ceb.2005.08.001, 16098727.
37. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003, 22:1381-1389. 10.1038/sj.onc.1206154, 12618764.
38. Song H, Jin X, Lin J. Stat3 upregulates MEK5 expression in human breast cancer cells. Oncogene 2004, 23:8301-8309. 10.1038/sj.onc.1208026, 15378007.
39. Li Z, Li J, Mo B, Hu C, Liu H, Qi H, Wang X, Xu J. Genistein induces cell apoptosis in MDA-MB-231 breast cancer cells via the mitogen-activated protein kinase pathway. Toxicol In Vitro 2008, 22:1749-1753. 10.1016/j.tiv.2008.08.001, 18761399.
40. Chen ST, Pan TL, Tsai YC, Huang CM. Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett 2002, 181:95-107. 10.1016/S0304-3835(02)00025-3, 12430184.
41. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998, 395:713-716. 10.1038/27234, 9790194.
42. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS. Novel ceramide analogues as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004, 309:523-532. 10.1124/jpet.103.062760, 14742741.
43. Frigo DE, Basu A, Simpson EN, Weldon CB, Dugan CB, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME. The p38 MAPK stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor interacting protein 1. Mol Endocrinol 2006, 20:971-983. 10.1210/me.2004-0075, 16410316.
44. Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, Tao H, Palmer ML, Holder KN, Lasky JA. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 2008, 283:21065-21073. 10.1074/jbc.M802786200, 18499657.
45. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔCT) method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
46. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995, 30:445-600. 10.3109/10409239509083491, 8770536.
47. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22:7369-7375. 10.1038/sj.onc.1206940, 14576844.
48. McLellan LI, Wolf CR. Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist Updat 1999, 2:153-164. 10.1054/drup.1999.0083, 11504486.
49. Hathout Y, Gehrmann ML, Chertov A, Fenselau C. Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett 2004, 210:245-253. 10.1016/j.canlet.2004.01.019, 15183541.
50. Tew KD, Monks A, Barone L, Rosser D, Akerman G, Montali JA, Wheatley JB, Schmidt DE. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol 1996, 50:149-159.
51. Wang K, Ramji S, Bhathena A, Lee C, Riddick DS. Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines. Xenobiotica 1999, 29:155-170. 10.1080/004982599238713, 10199592.
52. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54:4313-4320.
53. Monge M, Vilaseca M, Soto-Cerrato V, Montaner B, Giralt E, Perez-Tomas R. Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line. Invest New Drugs 2007, 25:21-29. 10.1007/s10637-006-7774-8, 16633713.
54. Steinert PM, Liem RK. Intermediate filament dynamics. Cell 1990, 60:521-523. 10.1016/0092-8674(90)90651-T, 2406023.
55. Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, Hendrix MJ. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res 1999, 5:2698-2703.
56. Athanassiadou P, Lazaris D, Athanassiades P, Kyrkou K, Petrakakou E, Keramopoulos K, Aravantinos D. Vimentin and alpha-fetoprotein expression in breast cancer smears: relationship with various prognostic factors. Cancer Detect Prev 1997, 21:207-212.
57. Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor RE. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 1996, 15:507-525. 10.1007/BF00054016, 9034607.
58. Fuchs IB, Lichtenegger W, Buehler H, Henrich W, Stein H, Kleine-Tebbe A, Schaller G. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 2002, 22:3415-3419.
59. Côme C, Magnino F, Bibeau F, Santa Barbara P, Becker KF, Theillet C, Savagner P. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006, 12:5395-5402. 10.1158/1078-0432.CCR-06-0478, 17000672.
60. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007, 26:6979-6988. 10.1038/sj.onc.1210508, 17486063.
61. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000, 2:84-89. 10.1038/35000034, 10655587.
62. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000, 2:76-83. 10.1038/35000025, 10655586.
63. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002, 62:1613-1618.
64. Côme C, Arnoux V, Bibeau F, Savagner P. Roles of the transcription factors snail and slug during mammary morphogenesis and breast carcinoma progression. J Mammary Gland Biol Neoplasia 2004, 9:183-193. 2259229, 15300012, 10.1023/B:JOMG.0000037161.91969.de.
65. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 12189386, 10.1038/nrc822.
66. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion and metastasis. J Cell Biol 2000, 148:779-790. 2169367, 10684258, 10.1083/jcb.148.4.779.
67. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999, 147:631-644. 2151177, 10545506, 10.1083/jcb.147.3.631.
68. Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 2007, 67:3106-3116. 10.1158/0008-5472.CAN-06-3401, 17409417.